Laser Treatment of Vulvovaginal Atrophy (VVA)

This policy addresses use of vaginal laser therapies (primarily fractional CO2 devices) for treatment of vulvovaginal atrophy/genitourinary syndrome of menopause in symptomatic women, including postmenopausal and perimenopausal patients and those with VVA related to oophorectomy, estrogen‑lowering treatments, breastfeeding, radiation/oncologic ovarian failure, or dissatisfaction with local estrogen. Major limitations: laser treatment for VVA is considered experimental/investigational and not covered, no vaginal laser device is FDA‑cleared for these indications, the evidence is limited (small, short‑term, uncontrolled studies), and members/providers must consult the member’s benefit plan and medical policy ADM1001.028 for coverage and dates of service on/after 2026‑01‑01.

"Vulvovaginal atrophy (VVA) associated with medications that decrease estrogen levels (e."